Free Trial
NASDAQ:NXL

Nexalin Technology 11/13/2023 Earnings Report

Nexalin Technology logo
$0.96 +0.05 (+4.92%)
As of 10:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nexalin Technology EPS Results

Actual EPS
-$0.31
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nexalin Technology Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nexalin Technology Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Nexalin Technology Earnings Headlines

Overnight moves = possibly bigger returns
Here’s a chart everyone should see that dates back to 1993… As you can see, the top line shows the much bigger average market return from trading overnight… Versus the bottom line, which shows the more modest average return from trading during the day. Look at that gigantic difference! So if you prefer nice big overnight returns instead, I agree with you. That’s why I’ve designed a breakthrough trade to tap into that overnight trading frenzy. You can check that out right here. Obviously, I won’t make any reckless guarantees in the stock market, but… That eye-opening chart above is just the beginning of the benefits you’ll see to trading overnight. PLUS, you’ll also see what my #1 ranked asset is in the entire market… And what my “hands-off” stocks are that I wouldn’t touch with a 100-foot pole.tc pixel
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL), a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

View Nexalin Technology Profile

More Earnings Resources from MarketBeat